Brought to you by 
Series A-1 brings in $6.8mm for Cerecor
27 Sep 2013
Executive Summary
Cerecor Inc. (neurology and respiratory therapeutics) raised $6.8mm through its Series A-1 preferred stock financing to 146 undisclosed investors. The company will use the funds to complete the technology transfer of CERC301 (a Phase II-ready selective NR2B antagonist for depression) and the COMT platform from Merck & Co. Inc. Cerecor has raised $30mm since its 2011 inception.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com